Authors
S Vasudevan, Professor, Department of Urology, Medical College, Trivandrum; Chief Editor, Kerala Medical Journal
Abstract
Background: India, despite impressive immunization efforts, faces plateaued full vaccination coverage (65%) and a high burden of vaccine-preventable diseases (VPDs), including measles and rubella. Measles is a leading cause of childhood mortality, and rubella causes congenital rubella syndrome (CRS) leading to irreversible birth defects.
Objective: To eliminate measles and control rubella/CRS by 2020, in line with resolutions from South-East Asia Regional Countries, India launched one of the world’s largest Measles-Rubella (MR) vaccination campaigns.
Methods: Following recommendations from the National Technical Advisory Group on Immunization (NTAGI), the MR campaign commenced on February 5, 2017. It targets over 41 crore children aged 9 months to less than 15 years nationwide, irrespective of their prior vaccination status or disease history. The campaign involves a single, free dose of MR vaccine delivered in public and private settings, including schools and health facilities, with technical support from WHO. Post-campaign, the MR vaccine will be integrated into the routine immunization schedule, replacing existing measles vaccine doses.
Conclusion: This national campaign is a critical step towards reducing childhood mortality and addressing birth defects, aiming to boost immunity and eliminate measles and rubella transmission, similar to successful efforts in other regions. Addressing vaccine hesitancy through active engagement with parents is crucial for the campaign’s success.